Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Mengqi, Jakobsson, Vivianne, Greifenstein, Lukas, Khong, Pek-Lan, Chen, Xiaoyuan, Baum, Richard P., Zhang, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767967/
https://www.ncbi.nlm.nih.gov/pubmed/36569154
http://dx.doi.org/10.3389/fmed.2022.1034315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767967/
https://www.ncbi.nlm.nih.gov/pubmed/36569154
http://dx.doi.org/10.3389/fmed.2022.1034315

Ejemplares similares